Sjoerd van Marle

Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee et al. · Clinical Therapeutics · 2012 · 96 citations

Medicine, Pharmacokinetics, Pharmacology +7

Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers

Cornelia Weber, Rita Schmitt, Herbert Birnboeck et al. · The Journal of Clinical Pharmacology · 1999 · 92 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients

M. C. Hoogstraten, Rutger J. Ploeg, W. Van den Burg et al. · Acta Neurologica Scandinavica · 1988 · 73 citations

Medicine, Neurology, Rehabilitation Medicine +17

Sugammadex is cleared rapidly and primarily unchanged via renal excretion

Pierre Peeters, Paul Passier, Jean Smeets et al. · Biopharmaceutics & Drug Disposition · 2011 · 57 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

Anthony Cahn, Simon T. Hodgson, Robert C. Wilson et al. · BMC Pharmacology and Toxicology · 2013 · 54 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11